Effect of amiloride on lithium-induced chronic nephropathy.
Recruiting
- Conditions
- lithiumnefropathielithiumnephropathy
- Registration Number
- NL-OMON20246
- Lead Sponsor
- does not apply
- Brief Summary
none
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
1. Patients on chronic lithium therapy and progressive renal function loss, defined as a plasma creatinine concentration increase of at least 10 umol/l/year during at least 5 years, a correlation
coefficient of 0.85 on linear regression analysis and a maximum plasma creatinine value of 200
umol/l;
Exclusion Criteria
1. Inability to give informed consent. (e.g. manic or depressiee episode, at discretion of psychiatrist);
2. Pregnancy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The result of combining lithium with amiloride should be reflected in a change in the course of de plasma<br>creatinine concentration (at least cutting in half the slope of the plasma creatinine concentration) within 9 months.
- Secondary Outcome Measures
Name Time Method